Cargando…

Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer

In localized prostate cancer (PCa), Grade Group (GG) and Gleason Score (GS) have a well-established prognostic role. In metastatic castration resistant prostate cancer (mCRPC), the prognostic role of GS and GG is less defined. In first-line treatment of mCRPC, androgen receptor (AR)-directed drugs (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cursano, M. C., Conteduca, V., Scarpi, E., Gurioli, G., Casadei, C., Gargiulo, S., Altavilla, A., Lolli, C., Vincenzi, B., Tonini, G., Santini, D., De Giorgi, U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072417/ https://www.ncbi.nlm.nih.gov/pubmed/35513478 http://dx.doi.org/10.1038/s41598-022-10751-6

Ejemplares similares

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer
por: Conteduca, V., et al.
Publicado: (2017)

Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
por: Conteduca, Vincenza, et al.
Publicado: (2022)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Plasma Androgen Receptor in Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer
por: Cursano, Maria Concetta, et al.
Publicado: (2023)

CAR-T cell therapy: a potential new strategy against prostate cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy
por: Cursano, Maria Concetta, et al.
Publicado: (2020)

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
por: Del Re, M., et al.
Publicado: (2021)

Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel
por: Gurioli, Giorgia, et al.
Publicado: (2022)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
por: Brighi, Nicole, et al.
Publicado: (2019)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
por: Iuliani, Michele, et al.
Publicado: (2022)

Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2016)

Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
por: Maiorano, B.A., et al.
Publicado: (2022)

Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms
por: Ribelli, Giulia, et al.
Publicado: (2021)

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
por: Conteduca, V., et al.
Publicado: (2017)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
por: Lavaud, Pernelle, et al.
Publicado: (2020)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
por: Salvi, S, et al.
Publicado: (2015)

Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer
por: Han, G. Celine, et al.
Publicado: (2017)

THU544 Prostatic Acid Phosphatase Is Negatively Regulated By Androgens And Persists In Castrate-resistant Metastatic Prostate Cancer
por: Rajagopalan, Vinodh, et al.
Publicado: (2023)

Vitamin D status among long-term survivors of testicular cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2016)

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone
por: De Giorgi, Ugo, et al.
Publicado: (2014)

The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
por: Gunter, Jennifer H., et al.
Publicado: (2012)

Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss
por: Markowski, Mark C., et al.
Publicado: (2022)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Jang, Ho Seong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_431qibprkn47vd367qufdu800e